BAY , a novel ADC with potent anti-tumor activity, targeting all isoforms of FGFR2
|
|
- Abigayle Benson
- 7 years ago
- Views:
Transcription
1 BAY , a novel ADC with potent anti-tumor activity, targeting all isoforms of FGFR2 6 th World ADC, San Diego, October 20, 2015 Anette Sommer
2 Disclosure Information I have the following financial relationships to disclose: I am an employee of BAYER AG I hold shares of BAYER AG I will not discuss off-label use and / or investigational use in my presentation Page 2 6 th ADC Summit San Diego, 2015
3 Bayer s Clinical Antibody Conjugate Pipeline Antibody-Drug Conjugates - ADCs Anetumab ravtansine: Mesothelin-DM4, to enter into Phase 2 BAY , C4.4a-ADC novel auristatin, Phase 1 dose escalation ongoing BAY , FGFR2-ADC novel auristatin, Phase 1 dose escalation ongoing Targeted Thorium Conjugates - TTCs See also presentation by Urs Hagemann on Oct. 21 Page 3 6 th ADC Summit San Diego, 2015
4 FGFR2 Fibroblast Growth Factor Receptor 2 FGFR2 is a transmembrane receptor tyrosine kinase FGFR2 signaling is involved several biological processes during Embryonic development Tissue homeostasis e.g. Cell proliferation Survival Differentiation Migration Low level of expression in normal human tissues and organs Page 4 6 th ADC Summit San Diego, 2015
5 Isoforms of FGFR2 in the Extracellular Domain (ECD) Alternative splicing in the IgG domains results in FGFR2 isoforms with different ligand binding & expression pattern Deletion of D1 in FGFR2 alpha isoform FGFR2 beta isoform Splicing within D3 IIIb (exons 7+8) IIIc (exons 7+9) A short sequence is contained in all 4 isoforms Binding epitope of BAY Page 5 6 th ADC Summit San Diego, 2015
6 FGFR2 Alterations in Cancer Protein/ RNA overexpression, eg. in gastric and breast cancer DNA amplification, eg. in gastric cancer and TNBC Associated with poor outcome, eg. of gastric Ca patients Constitutively active FGFR2 fusion proteins, eg. in cholangiocarcinoma, breast cancer, ovarian cancer Activating mutations, eg. in endometrial cancer Overexpression and amplification of FGFR2 in various solid cancer indications renders FGFR2 an interesting target for an ADC approach Page 6 6 th ADC Summit San Diego, 2015
7 BAY binds to all described splice variants of FGFR2 BAY : fully human IgG1 derived from the BioInvent n-coder library Binds to epitope at extreme N-terminus of FGFR2 Epitope is present in all described FGFR2 splice variants Epitope is 100% identical in human, monkey, rat, and murine FGFR2 Fully cross-reactive to orthologs of FGFR2 in human, monkey, rat, and mouse Response Binding of BAY to human N-terminal FGFR2 peptides (Biacore) Time K D = 75 nm ka (1/Ms) = 1.49 E +06 kd (1/s) = Rmax (RU) = Peptide and alanine scan-based epitope mapping A T L S L A R P S F S L V E D T T L E P E 250 Signal peptide Page 7 6 th ADC Summit San Diego, 2015
8 FGFR2 Ab BAY Induces Internalization of FGFR2 SUM-52PE BAY Rab7 lysosome M6PR late endosome 6h BAY induced receptor internalization correlates with FGFR2 FACS levels Co-localization of BAY with Rab7 indicates that most of the internalized antibody follows the lysosomal pathway Page 8 6 th ADC Summit San Diego, 2015
9 FGFR2-ADC BAY BAY is an antibody-drug conjugate directed against FGFR2 Two activities in one molecule Targeting of FGFR2 positive tumors with the FGFR2 Ab BAY Delivery of a highly cytotoxic payload of the auristatin class*) *) technology licensed from Seattle Genetics Page 9 6 th ADC Summit San Diego, 2015
10 Characteristics of BAY Mode-of-Action: microtubule destabilization 3.5x10 5 Pure, homogeneous preparation DAR ~3.8 DAR x10 5 tr = min Mw 146 kda 99.8 % (UV) x x10 5 molar mass (g/mol) 1.5x UV absorbance 1.0x10 5 SEC-MALS 5.0x10 4 tr = min 0.2 % (UV) time (min) Drug-to-antibody ratio from LC-MS Page 10 6 th ADC Summit San Diego, 2015
11 BAY inhibits proliferation of FGFR2 positive cells potently and selectively in vitro Cell Line Indication IC50 BAY [mol/l] KatoIII Gastric Ca SUM-52PE TNBC NCI-H716 CRC MFM-223 TNBC SNU-16 Gastric Ca KYSE-180 Esoph. Ca T1 TNBC FACS QuantiBrite : quantitative FACS analysis with BAY phycoerythrin (PE) 1:1 In vitro potency of BAY in cancer cells with FGFR2 Abs bound per cell MDA-MB-231 TNBC High potency & selectivity of BAY in vitro Potency in the subnanomolar range >100-fold selective vs. FGFR2-negative cell lines & control ADC Page 11 6 th ADC Summit San Diego, 2015
12 More than 30-fold enrichment of toxophore metabolite in FGFR2 positive NCI-H716 tumors in vivo Treatment of FGFR2 positive NCI-H716 tumor-bearing female NMRI nu/nu mice with BAY (5 mg/kg, i.v., SD) Page 12 6 th ADC Summit San Diego, 2015
13 BAY : dose-dependent & selective inhibition of SNU-16 gastric cancer model in vivo Tumor volume on day 32 [mm 3 ] [mg/kg] Vehicle Q4Dx3 Q10Dx3 Q4Dx3 * * * * Q4Dx3 DAR1.8 DAR4.5 DAR Q10Dx3 Tum or volum e [m ean ± SD, m m 3 ] **, p < 0.01; ***, p < ** *** *** *** Time after tumor cell inoculation [days] Vehicle BAY control-adc BAY , 5 mg/kg, DAR 1.8, Q4Dx3 BAY , 5 mg/kg, DAR 1.8, Q10Dx3 BAY , 5 mg/kg, DAR 4.5, Q4Dx3 Q10Dx3 Q7Dx3 BAY , 5 mg/kg, DAR 4.5, Q10Dx3 control-adc, 5 mg/kg, DAR 4.7, Q4Dx3 control-a D C, 5 m g/kg, D A R 4.7, Q 10D x3 Page 13 6 th ADC Summit San Diego, 2015
14 BAY : high in vivo efficacy in SNU-16 gastric cancer model and well tolerated in mice Tumor weight Body weight *, p < MED in SNU-16: 1.25 mg/kg at Q7Dx3 with a T/C of 0.24 (day 36) BAY was well tolerated, only 10 mg/kg reversibly affecting body weight Page 14 6 th ADC Summit San Diego, 2015
15 BAY Complete Responses in GA0033 gastric cancer PDX model 1500 GA0033 Tumor volume FGFR2, RNAscope, 40x Tum or volum e [m ean ± SD, m m 3 ] Tim e after first treatm ent [days] * * Vehicle BAY , 7.5 mg/kg, Q7Dx3 control-adc, 7.5 mg/kg, Q7Dx3 V inorelbine, 10 m g/kg, Q 7D x3 *, p < 0.05; n=5 GA0033 is a PDX model derived from a gastric cancer with high level of FGFR2 amplification and RNA and protein overexpression Page 15 6 th ADC Summit San Diego, 2015
16 BAY Complete Responses & high selectivity in MFM-223 model Tumor volume Waterfall plot 340 Vehicle **, p < 0.01; ***, p < BAY , 1 mg/kg, Q7Dx3 Tum or volum e [m ean ± SD, m m 3 ] BAY , 5 mg/kg, Q7Dx3 contro l-a D C, 1 m g/kg, Q 7D x3 contro l-a D C, 5 m g/kg, Q 7D x3 Doxorubicin, 10 mg/kg, Q14D Time after tumor cell inoculation [days] MFM-223 is a TNBC model with FGFR2 amplification and RNA/ protein overexpression ** *** *** Final tumor weight [mg] [mg/kg] Vehicle Control-ADC * * * BAY control-adc Doxorubicin Page 16 6 th ADC Summit San Diego, 2015
17 BAY high in vivo efficacy in BR1115 breast cancer PDX model 1500 Vehicle BR1115 ***, p < 0.001, n=5 FISH: FGFR2 / CEN10 Tum or volum e [m ean ± SD, m m 3 ] BAY , 7.5 mg/kg, Q7Dx3 control-adc, 7.5 mg/kg, Q7Dx3 V inorelbine, 10 m g/kg, Q 7D x3 *** *** FGFR2, RNAscope, 40x Tim e after first treatm ent [days] BR1115 is a PDX model derived from a breast cancer with high level of FGFR2 amplification, RNA overexpression, and an FGFR2-GAB2 fusion gene Page 17 6 th ADC Summit San Diego, 2015
18 BAY in vivo efficacy in ovarian cancer Ov A PDX model FISH: FGFR2 *, p < 0.05 ; ***, p < 0.001; Q7Dx3 OV A is a PDX model derived from a mucinous type ovarian cancer with high level of FGFR2 amplification, RNA and protein overexpression Page 18 6 th ADC Summit San Diego, 2015
19 BAY Phase I Study Stage 1 Starting dose: based on preclinical toxicology data Cohort size n=3 Dose escalation following pre-defined dose levels guided by preclinical TK/TD and PK/PD evaluation Until at least 1 DLT or 2 drug-related AEs Grade 2 Stage 2 Consider all available safety data Perform dose-response modeling of DLT rates to identify MTD Select next dose adaptively (possibly close to MTD**) Final decision on next dose between investigator and sponsor C R M **DLT rate <20% Primary objectives Determine the safety, tolerability, and maximum tolerated dose (MTD) of BAY Secondary objectives Evaluate the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarkers, and tumor response profile of BAY Study is ongoing: NCT Page 19 6 th ADC Summit San Diego, 2015
20 BAY Summary BAY : potent and selective FGFR2-targeting ADC BAY Ab binds to all FGFR2 ECD isoforms Novel linker toxophore of the auristatin class The toxophore metabolite is enriched more than 30-fold in FGFR2 positive xenograft tumors compared to murine organs BAY induces tumor regressions (CRs and PRs) in FGFR2 positive TNBC and gastric cancer xenograft models in mice in monotherapy BAY is well tolerated A Phase I study with BAY is recruiting (NCT ) Page 20 6 th ADC Summit San Diego, 2015
IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationMonoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.
Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects
More informationASMS Regulated Bioanalysis Interest Group (RBIG) Workshop. Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis.
ASMS Regulated Bioanalysis Interest Group (RBIG) Workshop Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis June 17, 2014 Presiding: Dr. Keyang Xu (Genentech) and Dr. Fabio Garofolo
More informationHow To Treat Mesothelioma With A Tumor Stem Cell Inhibitor
FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationMaking the switch to a safer CAR-T cell therapy
Making the switch to a safer CAR-T cell therapy HaemaLogiX 2015 Technical Journal Club May 24 th 2016 Christina Müller - chimeric antigen receptor = CAR - CAR T cells are generated by lentiviral transduction
More informationNewsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective:
Newsletter This resume of the results from the phase 1 study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationTHE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA
THE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA Mitchell Keegan, Ph.D. Vice President of Development, Verastem, Inc. 1
More informationBiotherapeutics Drug Development
Biotherapeutics Drug Development Susan Hurst, Ph.D. University of Connecticut Bioanalytical Chemistry Spring 2011 April 19, 2011 Outline Background Therapeutic Modalities Examples of Challenges for Biotherapeutics
More informationHow to develop Antibody Drug Conjugates: Bioanalysis Contribution
How to develop Antibody Drug Conjugates: Bioanalysis Contribution Recommendations and survey results Presenter: Matt Barfield on behalf of the EBF TT43 7th Open Symposium 19 th November 2014 Barcelona
More informationWntResearch. Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer
WntResearch Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer Why WntResearch is developing novel anti-cancer drugs Approximately 55 000 Swedish citizens are diagnosed with cancer every
More informationChallenges in early clinical development of biologics
Challenges in early clinical development of biologics Peter Lloyd March 2011 Acknowledgements: Jennifer Sims, Phil Lowe, Sebastian Spindeldreher, Andrew Warren Protein therapeutics biologics Current generation
More informationA disease and antibody biology approach to antibody drug discovery
A disease and antibody biology approach to antibody drug discovery Björn Frendéus, PhD VP, Preclinical research Presenter: Björn Frendéus Date: 2011-11-08 1 Antibodies have revolutionized Cancer Treatment!
More informationTowards Well-Defined ADCs (Antibody Drug Conjugates)
Towards Well-Defined ADCs (Antibody Drug Conjugates) Next generation approach June 10, 2015 Dr. Yong Zu Kim, CEO and President LegoChem Biosciences, Inc. Antibody Drug Conjugates ADC binds to Antigen Endocytosis
More information12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma
12. November 2013 Jan Endell From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma The MorphoSys Pipeline 21 Clinical Programs, 82 Total Program
More informationNew Advances in Cancer Treatments. March 2015
New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within
More informationa Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
More informationPfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014
Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology November 17, 2014 Forward-looking statements Our discussions during this conference call will
More informationMicroRNA formation. 4th International Symposium on Non-Surgical Contraceptive Methods of Pet Population Control
MicroRNA formation mirna s are processed from several precursor stages Mammalian genomes seem to have 100 s of mirna s Nucleotides in positions 2-8 of an mirna are considered the mirna seed 5 Methyl-G
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY Torben Plesner, Henk Lokhorst, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson
More informationDevelopment and validation of neutralising anti-drug antibody (Nabs) assays
Development and validation of neutralising anti-drug antibody (Nabs) assays Clare Kingsley Sector Manager, Bioanalytical Sciences, Quotient Bioresearch EBF 2012 Overview Anti-drug antibody and neutralising
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationValidated Cell-Based Assays for Rapid Screening and Functional Characterization of Therapeutic Monoclonal Antibodies
Validated Cell-Based Assays for Rapid Screening and Functional Characterization of Therapeutic Monoclonal Antibodies Abhishek Saharia, Ph. D. Senior Product Manager Validation Assays Drug Discovery Evolution
More informationSUMMARY AND CONCLUSIONS
SUMMARY AND CONCLUSIONS Summary and Conclusions This study has attempted to document the following effects of targeting protein antigens to the macrophage scavenger receptors by maleylation. 1. Modification
More informationKMS-Specialist & Customized Biosimilar Service
KMS-Specialist & Customized Biosimilar Service 1. Polyclonal Antibody Development Service KMS offering a variety of Polyclonal Antibody Services to fit your research and production needs. we develop polyclonal
More informationA Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
More informationSession 6 Clinical Trial Assessment Phase I Clinical Trial
L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationCONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294
AD Award Number: W81XWH-08-1-0030 TITLE: Regulation of Prostate Cancer Bone Metastasis by DKK1 PRINCIPAL INVESTIGATOR: Gregory A. Clines, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Alabama at
More informationNon-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
More informationAeterna Zentaris. 11 th Annual Needham Healthcare Conference April 3, 2012. Committed to cure
11 th Annual Needham Healthcare Conference April 3, 2012 Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities
More informationAposense Enhancing Drug Effects
Aposense Enhancing Drug Effects Miri Ben-Ami, M.D. CEO IATI Biomed June 2013 Aposense Proprietary FORWARD LOOKING STATEMENTS The following slides contain forward-looking statements that include, but are
More informationGene Silencing Oligos (GSOs) Third Generation Antisense
Gene Silencing Oligos (GSOs) Third Generation Antisense Walter R. Strapps, Ph.D. Executive Director, RNA Therapeutics Idera Pharmaceuticals Cambridge, MA NASDAQ: IDRA www.iderapharma.com Idera is a leader
More informationLead optimization services
Lead optimization services The WIL Research Company (WRC) has extensive experience in fast track tailor-made screening strategies to help you with the challenging task of selecting your best candidate
More informationBreakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation May 2015
Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation May 2015 Forward-looking statements / safe harbor This presentation and the accompanying oral
More informationHER2 Testing in Breast Cancer
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
More informationBasic Overview of Preclinical Toxicology Animal Models
Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationContact Information Korea Health Industry Development Institute
AGM-130, a novel CDK inhibitor with a marked anti-tumor activity and reduced toxicity, targeting the triple negative breast cancer(tnbc) and tamoxifen-resistant estrogen receptor (ER) positive breast cancer
More informationDiabetes and Drug Development
Diabetes and Drug Development Metabolic Disfunction Leads to Multiple Diseases Hypertension ( blood pressure) Metabolic Syndrome (Syndrome X) LDL HDL Lipoproteins Triglycerides FFA Hyperinsulinemia Insulin
More informationGuidance for Industry
Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page Sponsor Novartis Generic Drug Name BGT6 Therapeutic Area of Trial Advanced solid malignancies Approved Indication Investigational Study Number CBGT6A0 Title A phase
More informationNONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
More informationCowen and Company 35 th Annual Healthcare Conference
Personalized Therapeutics The Power of Epigenetics Cowen and Company 35 th Annual Healthcare Conference March 2015 2013 Accomplishments Forward Looking Statements This presentation contains forward-looking
More informationB Cell Generation, Activation & Differentiation. B cell maturation
B Cell Generation, Activation & Differentiation Naïve B cells- have not encountered Ag. Have IgM and IgD on cell surface : have same binding VDJ regions but different constant region leaves bone marrow
More informationDMPK: Experimentation & Data
DMPK: Experimentation & Data Interpretation Mingshe Zhu, Mike S. Lee, Naidong Weng, and Mark Hayward Prerequisite: Entry-level scientists with hands on experience in LC/MS as well as advanced students
More informationApplications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities
Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities Vincent A. Miller, M.D. Foundation Medicine, Inc. AACR Annual Meeting 2012 Current Concepts session
More informationAnti-CD38 anti-cd3 bispecific antibody in multiple myeloma
Anti-CD38 anti-cd3 bispecific antibody in multiple myeloma David E. Szymkowski Senior Director, Biotherapeutics Proteins by Design 1960s...1980s...2000s... Where are the bispecific antibody drugs? J Exp.
More informationCustom Antibody Services
Custom Antibody Services Custom service offerings DNA sequence Plasmid Peptide Structure Protein Peptide Small molecule Cells Spleen Lymphocytes Antigen Preparation Immunization Fusion & Subcloning Expansion
More informationCUSTOM ANTIBODIES. Fully customised services: rat and murine monoclonals, rat and rabbit polyclonals, antibody characterisation, antigen preparation
CUSTOM ANTIBODIES Highly competitive pricing without compromising quality. Rat monoclonal antibodies for the study of gene expression and proteomics in mice and in mouse models of human diseases available.
More informationBrigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA
Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma
More informationHow To Understand The Effects Of A Drug On Your Health
Farmacologia degli inibitori TK e mtor Romano Danesi Professore ordinario di Farmacologia UOC Farmacologia Universitaria Azienda Ospedaliero-Universitaria Pisana Dipartimento di Medicina Interna Università
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL
More informationThis presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking
Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties
More informationTargeted Therapy in an Era of Genomic Medicine. George W. Sledge MD Stanford University
Targeted Therapy in an Era of Genomic Medicine George W. Sledge MD Stanford University Why Do Women Die of Breast Cancer? Bad biology Avoidable deaths Important subsets of breast cancers defined by molecular
More informationGenScript Antibody Services
GenScript Antibody Services Scientific experts, innovative technologies, proven performance We specialize in custom antibody production to empower your research Custom Polyclonal Antibody Production Custom
More informationSuperior TrueMAB TM monoclonal antibodies for the recognition of proteins native epitopes
Superior TrueMAB TM monoclonal antibodies for the recognition of proteins native epitopes Outlines Brief introduction of OriGene s mission on gene-centric product solution. TrueMAB monoclonal antibody
More informationBispecific antibodies with native chain structure
Bispecific antibodies with native chain structure 11.03.2014 Kristin Fritsch Natural function of antibodies I. Spasevska, Biosciences Master Reviews, 2014 IgG Antibody http://www.ebioscience.com/knowledge-center/antigen/immunoglobulin/structure.htm
More informationCD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,
More informationHuCAL Custom Monoclonal Antibodies
HuCAL Custom Monoclonal Antibodies Highly Specific Monoclonal Antibodies in just 8 Weeks PROVEN, HIGHLY SPECIFIC, HIGH AFFINITY ANTIBODIES IN 8 WEEKS WITHOUT HuCAL PLATINUM IMMUNIZATION (Human Combinatorial
More informationRegulatory perspective for successful antibody-drug conjugate development
Regulatory perspective for successful antibody-drug conjugate development Wen Jin Wu, M.D., Ph.D. Senior Investigator Division of Biotechnology Review and Research I Office of Biotechnology Products (OBP)
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationMAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères 91030 Evry Cedex. www.mabsolut.com. is involved at each stage of your project
Mabsolus-2015-UK:Mise en page 1 03/07/15 14:13 Page1 Services provider Department of MABSolys from conception to validation MAB Solut is involved at each stage of your project Creation of antibodies Production
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationH. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
More informationA customizable ADCC assay service for antibodies & fusion proteins.
Antibody Dependent Cell- Mediated Cytotoxicity (ADCC) Assay A customizable ADCC assay service for antibodies & fusion proteins. Our ADCC assay service accurately detects cell lysis based on LDH-release.
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationTesting Services for Large Molecule Drug Development
Testing Services for Large Molecule Drug Development Our mission is to extend our clients capabilities by combining scientific knowledge, capacity, regulatory expertise and flexibility to provide the trusted,
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationMUTATION, DNA REPAIR AND CANCER
MUTATION, DNA REPAIR AND CANCER 1 Mutation A heritable change in the genetic material Essential to the continuity of life Source of variation for natural selection New mutations are more likely to be harmful
More informationAVEO Pharmaceuticals: Technologies and Vision
AVEO Pharmaceuticals: Technologies and Vision Massachusetts Biotechnology Council Drug Discovery Committee February 19, 2009 MBC, Cambridge Ronan C. O Hagan Group Leader, Target Biology AVEO s Unique Niche
More informationBroad Spectrum, Targeted Approaches To Cancer Treatment
SELECTIVELY KILLING CANCER CELLS Broad Spectrum, Targeted Approaches To Cancer Treatment Safe Harbor The presentation made during this meeting and other statements by ArQule may contain forward-looking
More informationFuture Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
More informationTargeted Chemotherapy Delivery Platform. Igor Sherman, PhD President & CEO Richard Potts, Chairman
Targeted Chemotherapy Delivery Platform Igor Sherman, PhD President & CEO Richard Potts, Chairman 2014 Change in Age Adjusted US Death Rates by Cause Almost unchanged over 50 years Source: U.S. National
More informationTherapeutic Systems Immunology
Therapeutic Systems Immunology Coordination: Robert Preissner, Charité, Berlin 13 Partners from Berlin (7) Göttingen (1) Heidelberg (1) Rostock (2) Tübingen (1) Overview Intro / Mission Partners Systems
More informationTECHNICAL INSIGHTS TECHNOLOGY ALERT
TECHNICAL INSIGHTS TECHNOLOGY ALERT UNLOCKING BREAST CANCER TUMORS' DRUG RESISTANCE A troubling phenomenon in breast cancer treatment is that some patients tumors become resistant to treatments over time.
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationRoots Analysis Pvt. Ltd.
Roots Analysis Pvt. Ltd. http://www.marketresearch.com/rootsanalysispvt.ltd. -v3981/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am
More informationHUMORAL IMMUNE RE- SPONSES: ACTIVATION OF B CELLS AND ANTIBODIES JASON CYSTER SECTION 13
SECTION 13 HUMORAL IMMUNE RE- SPONSES: ACTIVATION OF B CELLS AND ANTIBODIES CONTACT INFORMATION Jason Cyster, PhD (Email) READING Basic Immunology: Functions and Disorders of the Immune System. Abbas,
More informationBioMmune Technologies Inc. Corporate Presentation 2015
BioMmune Technologies Inc Corporate Presentation 2015 * Harnessing the body s own immune system to fight cancer & other autoimmune diseases BioMmune Technologies Inc. (IMU) ABOUT A public biopharmaceutical
More informationApplications of Ab Molecules. Chapter 4 Monoclonal Ab (p.99) Chapter 5 Ab genes and Ab Engineering (p.128)
Applications of Ab Molecules Chapter 4 Monoclonal Ab (p.99) Chapter 5 Ab genes and Ab Engineering (p.128) Monoclonal Antibodies Clonal Selection of B Lymphocytes Hybridoma Köhler and Milsten (1975) - continuous
More informationChapter 8. Summary and Perspectives
Chapter 8 Summary and Perspectives 131 Chapter 8 Summary Overexpression of the multidrug resistance protein MRP1 confer multidrug resistance (MDR) to cancer cells. The contents of this thesis describe
More informationMATHEMATICAL MODELS OF TUMOR GROWTH INHIBITION IN XENOGRAFT MICE AFTER ADMINISTRATION OF ANTICANCER AGENTS GIVEN IN COMBINATION
MATHEMATICAL MODELS OF TUMOR GROWTH INHIBITION IN XENOGRAFT MICE AFTER ADMINISTRATION OF ANTICANCER AGENTS GIVEN IN COMBINATION Nadia Terranova UNIVERSITÀ DI PAVIA New model development: course of action
More informationRADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC
More informationT Cell Maturation,Activation and Differentiation
T Cell Maturation,Activation and Differentiation Positive Selection- In thymus, permits survival of only those T cells whose TCRs recognize self- MHC molecules (self-mhc restriction) Negative Selection-
More informationCHAPTER 8 IMMUNOLOGICAL IMPLICATIONS OF PEPTIDE CARBOHYDRATE MIMICRY
CHAPTER 8 IMMUNOLOGICAL IMPLICATIONS OF PEPTIDE CARBOHYDRATE MIMICRY Immunological Implications of Peptide-Carbohydrate Mimicry 8.1 Introduction The two chemically dissimilar molecules, a peptide (12mer)
More informationOPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone.
Title of the poster Authors Sheffield Cancer Research Centre University of Sheffield OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Dr Penelope Ottewell Background
More informationEndpoint Selection in Phase II Oncology trials
Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles
More informationRodman & Renshaw Annual Global Investment Conference. September 13, 2010
Rodman & Renshaw Annual Global Investment Conference September 13, 2010 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in
More informationDesign and Synthesis of Tubulin-derived Peptides as Molecular Imaging Probes that Target Tumor Cells.
Design and Synthesis of Tubulin-derived Peptides as Molecular Imaging Probes that Target Tumor Cells. AKENTIEVA NATALIA, PhD Laboratory Regional Cancer Research Program, LHSC Frequency of Cancer 2012 Distribution
More informationHapten - a small molecule that is antigenic but not (by itself) immunogenic.
Chapter 3. Antigens Terminology: Antigen: Substances that can be recognized by the surface antibody (B cells) or by the TCR (T cells) when associated with MHC molecules Immunogenicity VS Antigenicity:
More informationHow To Use Berberine
Programa Cooperación Farma-Biotech Jornada II: Oncología Novel Berberine derivatives as antitumor agents for cancer Barcelona, 13 de abril de 2011 Programa Cooperación Farma-Biotech Jornada II: Oncología
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationCellectar Biosciences
Cellectar Biosciences NASDAQ: CLRB September 2015 1 Safe Harbor Statement This slide presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation
More informationOncology Drug Development
Oncology Drug Development A Reviewers Personal Observations W. David McGuinn, Jr., M.S., Ph. D., D.A.B.T. 1 They Make Me Say This Disclaimer This presentation is not an official FDA guidance or policy
More informationTEMA 10. REACCIONES INMUNITARIAS MEDIADAS POR CÉLULAS.
TEMA 10. REACCIONES INMUNITARIAS MEDIADAS POR CÉLULAS. The nomenclature of cytokines partly reflects their first-described function and also the order of their discovery. There is no single unified nomenclature,
More informationCellectar Biosciences
Cellectar Biosciences NASDAQ: CLRB October 2015 1 Safe Harbor Statement This slide presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation
More informationDrug Development Services
Drug Development Services USING BLOOD AND BONE MARROW PRIMARY CELL SYSTEMS Clinically Relevant In Vitro Assays Broad Spectrum of Drug Classes Multi-Species Platforms Enhancing Drug Development through
More informationSummary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs
Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer
More information